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Abstract
Nanoparticles (NPs) include a wide
group of small structures composed by very
different materials and characterized by
peculiar properties that make them suitable
for many applications, especially imaging
and drug delivery. In this overview, we
focus on the optical properties of fluores-
cent NPs available for in vivo, in vitro and
ex vivo preclinical studies and detectable
with the optical imaging technique alone or
in combination with microscopic confocal
imaging. We summarize here the basic
principles of the optical detection of fluo-
rescent NPs, elucidating which are the cur-
rent issues to be resolved and possible solu-
tions to achieve the highest sensitivity and
specificity for an unbiased analysis. So far
NPs application in clinic is in evaluation
due to safety questions still unaddressed
but in the future they could dramatically
improve both preclinical research and
patient clinical care. 
Introduction
In the molecular imaging landscape a
wide variety of nanoparticles (NPs) with
many different physical chemical and phar-
macological features has recently
appeared.1,2 NPs are structures with all the
three dimensions sized in the range of 1-100
nanometers, made of metals, semiconduc-
tors or polymers, with peculiar optical,
magnetic, electronic and structural proper-
ties making them suitable for several in
vitro and in vivo applications. They are
designed especially for diagnostic imaging
purposes or as drug-carriers for therapy
studies,3,4 or for both diagnosis and therapy
opportunities in a single theranostic agent.5
Their implementation in clinic is currently
under evaluation.6 A summary of NPs’ prop-
erties is beyond of the aim of this overview;
here we will focus instead on the fluores-
cent properties of the NPs synthesized for
optical imaging (OI) applications (i.e., for
in vivo deep tissue analysis) with a glance
on the confocal microscopic imaging field
for a more detailed NPs localization in the
tissue at the cellular level.7-9
The term OI is sometimes used to indi-
cate a large variety of imaging techniques
based on the detection of optical photons
but more often it designates a specific tech-
nique, as we do throughout this overview,
developed for in vivo acquisition of optical
photons coming from small laboratory ani-
mals or, in general, from few centimeters
sized-samples. The great improvements of
OI in the last years are due to the high sen-
sitivity achieved by optical detectors and to
the high efficiency of the optical probes and
light sources, especially in the near infrared
region (NIR) of the light spectrum. In fact,
OI reveals photons in the ultraviolet (UV,
10-400 nm), visible (400-700 nm) and NIR
(700 nm - 1 mm) range, but only NIR pho-
tons travel through biological tissues with
minimal absorption, making them able to
reach deeper tissue levels.
Photon absorption
When photons pass through a biological
tissue, they can be absorbed by molecules
they interact with. The absorption is mod-
eled by the Lambert-Beer law which
describes how the number of photons in a
light beam is reduced in an exponential way
increasing the thickness of tissue slab.10 The
distance travelled by photons, represented
by the “mean free path before absorption, or
absorption length” is in a strict dependence
on the tissue optical properties and the light
wavelength. The absorption length can be
calculated by means of the Lambert-Beer
law as the depth at which the number of
photons in the beam is reduced to 1/e (e =
2.718), i.e. around 30% of the initial value.
Hemoglobin (both in oxidized and
reduced form), water, lipids and melanin are
the molecules with highest ability to absorb
photons of the optical light.11 The biological
tissues, instead, are optically thin in the
650-800 nm interval, called “NIR optical
window”, allowing photons of that spectral
region to travel a longer distance before
being absorbed. For instance, in the muscle
tissue, blue photons (450 nm) have a mean
absorption length of about 0.4 cm, whereas
NIR photons (800 nm) of 1.8 cm.12 The dif-
ferential photons’ absorption is clearly visi-
ble when a finger is placed on the white
LED of the cellular torch: only red photons
are visible on the opposite side of the finger
whereas the others are “lost” in the tissue.
This also explains why OI acquisition in the
NIR range is particularly suitable for pre-
clinical studies on small animal models (1.5
cm thick, in case of mice). On the other
hand, for the same reason, OI is only mar-
ginally used on humans so far, since most of
the organs are deeper than 2 cm and the
optical thickness reduces both the excitation
light, travelling from the surface to deeper
tissue layers, and the fluorescence emission
travelling to the surface, beyond which it
could be detected.
A molecule that adsorbs a photon is
excited to a higher vibrational energy level
and rapidly loses part of the energy as heat.
It eventually relaxes to the ground state
with the emission of lower energy photon.
This process, called “fluorescence”, is
almost instantaneous (10-8 s), thus fluores-
cence emission immediately ends after
switching off the excitation source.10 When
absorption/emission occurs in fluo-
rochromes naturally present in biological
structures, the emission is called “autofluo-
rescence” and mostly limits the sensitivity
of fluorescent imaging. Fluorescent dyes
loaded on or linked to NPs exploit the same
physical process to convert excitation in
emission light. The fluorescence of semi-
conductor NPs, like quantum dots (QDs), is
due to the same process which involves the
valence and the conduction bands instead of
single energy levels. 
Photon scattering
Before absorption, the critical processes
encountered by the light interacting with the
tissues can be photon reflection, refraction,
diffusion or scattering, which affect the
straight trajectory of the light inside a tis-
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sue.13 In particular, the elastic scattering
occurs when change of directions do not
cause energy losses (i.e., frequency).14
Moreover, a photon can be subjected to
multiple scattering events (10-1000) before
experiencing a fatal encounter with a mole-
cule and disappearing from the light beam.
Scattering events are responsible for the
“lack of memory” of the initial motion
direction of the photons. This is the reason
why, putting again a finger on the white
LED of the cellular torch, no sign of the fin-
ger’s bone can be observed. Contrary to 
x-ray imaging, in which high energy pho-
tons travel in straight direction inside the
soft tissues and are absorbed by bones, opti-
cal photons travel almost randomly in the
flesh around the bone from the light source
to the opposite surface and exit with many
different directions; thus the light emission
appears homogenous.15
OI instrument
Specifically designed instruments for
OI, named “optical imagers”, are usually
composed by a tight light box to prevent
contamination in the measurement from the
ambient light and a charge coupled device
(CCD) camera, which is a very sensitive
detector composed by 512 x 512 up to 2048
x 2048 pixels. To reduce the electronic
noise the CCD is cooled between -40 and -
90°C. The instruments are supplied with a
set of excitation and emission filters which
allow to choose specific excitation and
emission wavelengths respectively, in
accordance with the fluorescent dye proper-
ties. As light source, a xenon lamp or differ-
ent lasers (for example 635, 670, 745 and
790 nm in the FMT instrument, Perkin
Elmer, Waltham, MA, USA) are often
employed. Mice are placed under anesthesia
inside the instrument on a heated stage
(37°C) to preserve the body temperature
during acquisitions. A field of view (FoV)
from few to 20-30 cm allows imaging of
more than one, and up to five mice at the
same time. Diaphragm, binning (i.e., the
sensitivity of the CCD), exposure time and
focus height can also be selected by the
operator. At the end of each acquisition,
luminescent images are shown in pseudo-
colors that are associated to the intensity of
the light reaching each pixel and overlapped
with a picture of the animals to localize the
regions of light signal source. 
The quantification of fluorescence
emission is performed by tracing a region of
interest (ROI) on the luminescent images
and by calculating the light efficiency that is
obtained normalizing the fluorescent emis-
sion with the incident excitation intensities.
This measurement is not influenced by the
camera settings. The acquisition time used
generally for fluorescent imaging (FLI) is in
the order of seconds but it can go up to 10
min for 3D acquisitions, since they require
multiple exposures. 
Apart from fluorescence, OI is able to
detect also bioluminescence sources (biolu-
minescence imaging, BLI). The most repre-
sentative application is the light production
derived from the enzymatic reaction of
luciferin oxidation catalyzed by luciferase
enzyme for in vivo monitoring of tumor
growth or for in vivo16,17 and in vitro
reporter studies.18 In both scenarios, immor-
talized cells or mice used in these studies
need to be genetically engineered with
luciferase gene since they do not physiolog-
ically produce this protein. Recently, other
optical imaging-based applications were
developed exploiting the registration of the
Cerenkov luminescence (CLI)19-21 and of
the radioluminescence (RLI) both produced
by the interaction of radionuclides with
matters.22-24 Moreover, NPs used to shift the
blue glow of Cerenkov radiation have also
been investigated.25,26
Fluorescent NPs
In biological and preclinical studies,
fluorescent NPs are generally used to local-
ize molecules or highlight processes in cul-
tured cells or living organisms. In the latter,
it is noteworthy that both excitation and
emission lights are subjected to absorption
and scattering; therefore, both excitation
and emission wavelengths should be in the
NIR optical window to allow good signal
detection. Consequently, best OI-optimized
florescent NPs have 700-750 nm excitation
and 750-800 nm emission wavelengths,
respectively.27 The CCD cameras mounted
on OI instruments are generally optimized
for visible photon acquisitions but are still
sensitive (even if with reduced sensitivity)
in the NIR range, thus they can detect pho-
tons in the 800-850 nm wavelength range.
Working with high efficient NPs is manda-
tory in order to obtain a good signal to noise
ratio and to achieve low exposure time
acquisitions; if the efficiency of the NPs is
too low, the specific signal of the particles
can be covered by autofluorescence of the
tissues,28 especially of the skin.29 Thus,
nonetheless NIR-developed dyes are more
suitable for deep-tissue imaging, autofluo-
rescence can still limit detection sensitivity. 
OI is a very versatile, fast and non-inva-
sive technology but have some limitations:
first of all, OI alone is not sufficient to accu-
rately define NPs localization. In other
words, most of OI instruments provide 2D
images without any information of the
sources’ depth. New generation instruments
and 3D modeling software30,31 tried to fill
this gap. However, 3D reconstructions of
fluorescent images require longer exposure
times and the results are affected by the
hypothesis on which the software is based.
Secondly, the scattering process creates a
spot of light on the imaged surface also in
the case of perfectly point sources inside the
tissues. Finally, photon absorption can lead
to a misunderstanding of the light signal
distribution. For example, lack of light sig-
nal in a specific anatomic region could be
interpreted as absence of NPs instead of
high photon tissue absorption.
Consequently, also the shape of target
organs could be altered by the absorption of
different tissue layers interposed between
the emission sources and the detector.15
However, lower resolution and signal
broadening are rewarded by very high sen-
sitivity, aiming to single fluorescently
labelled cell detection, at least for in vitro
acquisitions. For example, for dual contrast
agents (MRI - OI) only one fluorophore is
needed for optical detection against 100
molecules with magnetic properties for
MRI visualization. 
To improve NPs tissue localization with
OI, an acquisition of the dissected organs is
often suggested. Unfortunately, the time
lapse necessary for ex vivo acquisitions crit-
ically affects the morphological architecture
of the tissue (especially for those requiring
immediate fixation, such as pancreas) mak-
ing them almost useless for further micro-
scopic investigations. Moreover, an untreat-
ed control group, which does not receive
NPs, is always necessary to establish
organs’ autofluorescence emission in order
to evaluate statistically significant differ-
ences with the treated group. Finally, perfu-
sion of the animals is required to remove
NPs in the blood vessels and to acquire flu-
orescence emission from NPs in the
parenchima. In conclusion, transmission
electron microscopy (TEM) or optical
microscopic investigations are still manda-
tory to perform an unbiased analysis. The
second ones are conducted on very thin tis-
sue sections (few μm) so light absorption
and scattering issues are highly reduced.
However, the light emitted by NPs, is cap-
tured by photomultiplier (PMT) detectors
optimized for the acquisition of UV-visible
photons and which are almost blind to NIR
wavelengths. One possible solution is to use
or synthesize NPs with “bluer” emission
respect to the “optimum”, i.e. around 700
nm that is still detectable by PMTs. This
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requires an excitation wavelength at least at
the beginning of the NIR window. This
approach represents a compromise to detect
NPs both in vivo (OI) and ex vivo (confocal
imaging).
Another approach to obtain NPs with
optical properties suitable for both OI and
microscopic imaging is to synthesize them
with two different fluorophores.32 Avoiding
cross-contamination of the light signal and
unwanted chemical reactions between the
two fluorophores, one of them must be cho-
sen in order to obtain excitation/emission of
750/800 nm for OI acquisitions. Instead, for
confocal imaging the requirements are less
compelling. Many laser lines can be used
for confocal microscopy (405, 458, 475,
488, 495, 514, 543, and 633 nm in a diffuse
TCS SP5 Leica system) and the range of
PMTs sensitivity can be set freely. An
example is the NP synthesis with cyanine
(Cy) and rhodamine in the silica matrix.
The first one (830 nm / 855 nm) is opti-
mized for OI, the second one (570 nm / 587
nm) for confocal imaging.32
Organic fluorophores and quan-
tum dots
In the optical imaging field, many kind
of fluorophores can be enrolled. They are
mainly classified as molecular systems with
a defined structure which include organic
and biologically-derived fluorophores,
nanocrystal such as QDs and nanometer- to
micrometer-sized particles with size inde-
pendent optical features.33 For biomedical
imaging applications, the most useful nano-
sized fluorescent dyes are organic fluo-
rophores conjugated or inserted in NPs
structures and QDs. A comparison between
organic fluorophores and QDs can be found
in literature.34
Organic fluorophores can be synthe-
sized with many different emission wave-
lengths but they show a poor difference
between excitation and emission peaks
(Stokes shift) up to 50 nm. Low photostabil-
ity (stability against chemical reactions
induced by the incoming radiation) and
high photobleaching (photochemical alter-
ation of a dye or a molecule which perma-
nently blocks its ability to fluoresce) gener-
ally represent other issues for their applica-
tions. Keeping in mind the optical require-
ments for in vivo applications, Cy5.5 
(675 nm / 694 nm) Cy7 (743 nm / 767 nm),
Indocyanine green (ICG, 788 nm / 813 nm)
and Alexa Fluor 750 (752 nm / 776 nm) are
good choices.
On the other hand, QDs (1-6 nm core
diameter) are very bright fluorophores
made from nanocrystals of semiconductor
material35,36 with peculiar optical properties
and advantages: efficiency 20-30 times
higher than organic fluorophores, size-tun-
able emission, extremely broad excitation
range and narrow emission which allow
large Stokes shift (resulting in an increase
of the signal/noise ratio in case of tissue 
autofluorescence). High photostability and
low photobleaching are their strength, often
assured by an outer shell which protects the
NP core. Unfortunately, QDs toxicity, espe-
cially of those containing cadmium (i.e.,
CdSe and CdTe), limits their use in vivo and
leads to the development of new kind of
QDs with less harmful chemical elements,
such as InP/InGaP QDs. For OI applica-
tions, QDs with emission at 750-800 nm
range are the best choice.
The blinking, or fluorescence intermit-
tency, is the switching between ON and
OFF (bright and dark) states of the emitters
under continuous excitation, with the latter
being a property of the nanoscale fluo-
rophores (both molecular fluorophores and
QDs).37,38 For in vivo acquisitions, where
only macroscopic effects are detectable
(due to the relatively long exposure time
and the stochastic nature of the light propa-
gation), it results in a reduction of the fluo-
rescent light signal. 
Conclusions
Optical imaging is a noninvasive tech-
nology that exploits physical properties of
molecules to highlight specific biological
processes. Nonetheless the limitations of
both OI technique (tissue adsorption, scat-
tering) and dyes (photobleaching, photosta-
bility, blinking) the main concern is repre-
sented by NPs’ toxicity. Most of them con-
tain elements with carcinogenic, immuno-
toxic action, such as cadmium and selenium
based QDs. Moreover, concentration, size,
outer coating bioactivity, charge, and oxida-
tive, mechanical and photolytic stability
also play a role in determining NPs’ toxici-
ty.39 Thus, a great effort is currently being
spent to fill this requirement. However,
advances in optical instrumentation and
new contrast agents allowed to enhance
sensitivity and specificity for example of
cancer cell detection, providing significant
help to surgeon in visualizing cancer mar-
gins during tumor resections. NPs’ func-
tionalization with ligands targeting cellular
surface proteins40-42 or cellular metabolic
biomarkers (pH, oxidative stress or activa-
tion of peculiar proteases),43 increased as
well sensitivity and specificity of detection
in preclinical settings. In the last years, ther-
anostic application of NPs were also inves-
tigated in preclinical settings providing
encouraging results.44,45 These studies will
be soon translated in new diagnostic tools to
detect the pathology at the earliest stages,
therefore increasing the therapeutic inter-
vention window and patient clinical out-
come. 
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